Reshma Jagsi1, Paul H Abrahamse2, Kamaria L Lee1, Lauren P Wallner3, Nancy K Janz4, Ann S Hamilton5, Kevin C Ward6, Monica Morrow7, Allison W Kurian8, Christopher R Friese9, Sarah T Hawley10, Steven J Katz11. 1. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 2. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 3. Departments of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, Michigan. 4. Department of Health Behavior and Health Education, University of Michigan, Ann Arbor, Michigan. 5. Keck School of Medicine, Department of Preventive Medicine, University of Southern California, Los Angeles, California. 6. Department of Epidemiology, Emory University, Atlanta, Georgia. 7. Memorial Sloan-Kettering Cancer Center, New York, New York. 8. Departments of Medicine and Health Research and Policy, Stanford University, Stanford, California. 9. Department of Systems, Populations and Leadership, University of Michigan, Ann Arbor, Michigan. 10. Departments of Internal Medicine and Health Management and Policy, University of Michigan and Ann Arbor VA Health Care System, Center for Clinical Management Research, Ann Arbor, MI. 11. Department of Internal Medicine and Health Management and Policy, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Many patients with breast cancer work for pay at the time of their diagnosis, and the treatment plan may threaten their livelihood. Understanding work experiences in a contemporary population-based sample is necessary to inform initiatives to reduce the burden of cancer care. METHODS: Women who were 20 to 79 years old and had been diagnosed with stage 0 to II breast cancer, as reported to the Georgia and Los Angeles Surveillance, Epidemiology, and End Results registries in 2014-2015, were surveyed. Of the 3672 eligible women, 2502 responded (68%); 1006 who reported working before their diagnosis were analyzed. Multivariate models evaluated correlates of missing work for >1 month and stopping work altogether versus missing work for ≤1 month. RESULTS: In this diverse sample, most patients (62%) underwent lumpectomy; 16% underwent unilateral mastectomy (8% with reconstruction); and 23% underwent bilateral mastectomy (19% with reconstruction). One-third (33%) received chemotherapy. Most (84%) worked full-time before their diagnosis; however, only 50% had paid sick leave, 39% had disability benefits, and 38% had flexible work schedules. Surgical treatment was strongly correlated with missing >1 month of work (odds ratio [OR] for bilateral mastectomy with reconstruction vs lumpectomy, 7.8) and with stopping work altogether (OR for bilateral mastectomy with reconstruction vs lumpectomy, 3.1). Chemotherapy receipt (OR for missing >1 month, 1.3; OR for stopping work altogether, 3.9) and race (OR for missing >1 month for blacks vs whites, 2.0; OR for stopping work altogether for blacks vs whites, 1.7) also correlated. Those with paid sick leave were less likely to stop working (OR, 0.5), as were those with flexible schedules (OR, 0.3). CONCLUSIONS: Working patients who received more aggressive treatments were more likely to experience substantial employment disruptions. Cancer 2017;123:4791-9.
BACKGROUND: Many patients with breast cancer work for pay at the time of their diagnosis, and the treatment plan may threaten their livelihood. Understanding work experiences in a contemporary population-based sample is necessary to inform initiatives to reduce the burden of cancer care. METHODS:Women who were 20 to 79 years old and had been diagnosed with stage 0 to II breast cancer, as reported to the Georgia and Los Angeles Surveillance, Epidemiology, and End Results registries in 2014-2015, were surveyed. Of the 3672 eligible women, 2502 responded (68%); 1006 who reported working before their diagnosis were analyzed. Multivariate models evaluated correlates of missing work for >1 month and stopping work altogether versus missing work for ≤1 month. RESULTS: In this diverse sample, most patients (62%) underwent lumpectomy; 16% underwent unilateral mastectomy (8% with reconstruction); and 23% underwent bilateral mastectomy (19% with reconstruction). One-third (33%) received chemotherapy. Most (84%) worked full-time before their diagnosis; however, only 50% had paid sick leave, 39% had disability benefits, and 38% had flexible work schedules. Surgical treatment was strongly correlated with missing >1 month of work (odds ratio [OR] for bilateral mastectomy with reconstruction vs lumpectomy, 7.8) and with stopping work altogether (OR for bilateral mastectomy with reconstruction vs lumpectomy, 3.1). Chemotherapy receipt (OR for missing >1 month, 1.3; OR for stopping work altogether, 3.9) and race (OR for missing >1 month for blacks vs whites, 2.0; OR for stopping work altogether for blacks vs whites, 1.7) also correlated. Those with paid sick leave were less likely to stop working (OR, 0.5), as were those with flexible schedules (OR, 0.3). CONCLUSIONS:Workingpatients who received more aggressive treatments were more likely to experience substantial employment disruptions. Cancer 2017;123:4791-9.
Authors: Mahasin S Mujahid; Nancy K Janz; Sarah T Hawley; Jennifer J Griggs; Ann S Hamilton; Steven J Katz Journal: Breast Cancer Res Treat Date: 2009-04-10 Impact factor: 4.872
Authors: Monica Morrow; Paul Abrahamse; Timothy P Hofer; Kevin C Ward; Ann S Hamilton; Allison W Kurian; Steven J Katz; Reshma Jagsi Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: Amanda R Sergesketter; Samantha M Thomas; Whitney O Lane; Jonah P Orr; Ronnie L Shammas; Oluwadamilola M Fayanju; Rachel A Greenup; Scott T Hollenbeck Journal: Plast Reconstr Surg Date: 2019-06 Impact factor: 4.730
Authors: Whitney H Beeler; Emily L Bellile; Keith A Casper; Elizabeth Jaworski; Nicholas J Burger; Kelly M Malloy; Matthew E Spector; Andrew G Shuman; Andrew Rosko; Chaz L Stucken; Steven B Chinn; Aleksandar F Dragovic; Christina H Chapman; Dawn Owen; Shruti Jolly; Carol R Bradford; Mark E P Prince; Francis P Worden; Reshma Jagsi; Michelle L Mierzwa; Paul L Swiecicki Journal: Oral Oncol Date: 2019-12-23 Impact factor: 5.337
Authors: Florence K L Tangka; Sujha Subramanian; Madeleine Jones; Patrick Edwards; Timothy Flanigan; Yevgeniya Kaganova; Kevin W Smith; Cheryll C Thomas; Nikki A Hawkins; Juan Rodriguez; Temeika Fairley; Gery P Guy Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-03 Impact factor: 4.254
Authors: Shoshana M Rosenberg; Ines Vaz-Luis; Jingyi Gong; Padma Sheila Rajagopal; Kathryn J Ruddy; Rulla M Tamimi; Lidia Schapira; Steven Come; Virginia Borges; Janet S de Moor; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2019-05-30 Impact factor: 4.872
Authors: Rachel A Greenup; Christel Rushing; Laura Fish; Brittany M Campbell; Lisa Tolnitch; Terry Hyslop; Jeffrey Peppercorn; Stephanie B Wheeler; S Yousuf Zafar; Evan R Myers; E Shelley Hwang Journal: J Oncol Pract Date: 2019-07-29 Impact factor: 3.840
Authors: Allison W Kurian; Kevin C Ward; Ann S Hamilton; Dennis M Deapen; Paul Abrahamse; Irina Bondarenko; Yun Li; Sarah T Hawley; Monica Morrow; Reshma Jagsi; Steven J Katz Journal: JAMA Oncol Date: 2018-08-01 Impact factor: 31.777
Authors: Shoshana Adler Jaffe; Dolores D Guest; Andrew L Sussman; Charles L Wiggins; Jessica Anderson; Jean A McDougall Journal: Cancer Causes Control Date: 2021-06-27 Impact factor: 2.506